Patient characteristics
Variable . | n . | % . |
---|---|---|
Age, median (range), y | 55 (23-69) | — |
Sex | ||
M | 9 | 56 |
F | 7 | 44 |
Conditioning intensity | ||
Myeloablative | 12 | 75 |
Reduced | 4 | 25 |
Disease | ||
AML | 12 | 75 |
MDS | 4 | 25 |
Donor | ||
Matched related | 6 | 37 |
Matched unrelated | 7 | 44 |
Mismatched related (haploidentical) | 3 | 19 |
Status at HCT | ||
CR1 | 7 | 44 |
CR2 | 2 | 12 |
Not in remission | 7 | 44 |
Cytogenetic risk | ||
Monosomal (+) | 9 | 56 |
Monosomal (−) | 7 | 44 |
Molecular | ||
TP53 (+) | 6 | 37 |
TP53 (−) | 7 | 44 |
TP53 (n/a) | 3 | 19 |
BM blast % at relapse (AML + MDS), median (range) | 21.5 (5-92) | - |
BM blast % at relapse (AML), median (range) | 26.5 (5-92) | - |
Prior GVHD before Pembrolizumab | ||
No | 10 | 63 |
Yes | 6 | 37 |
On immune suppression at pembrolizumab start | ||
No | 11 | 69 |
Yes | 5 | 31 |
Time of relapse post-HCT (range), d | 168.5 (66-1064) | - |
Variable . | n . | % . |
---|---|---|
Age, median (range), y | 55 (23-69) | — |
Sex | ||
M | 9 | 56 |
F | 7 | 44 |
Conditioning intensity | ||
Myeloablative | 12 | 75 |
Reduced | 4 | 25 |
Disease | ||
AML | 12 | 75 |
MDS | 4 | 25 |
Donor | ||
Matched related | 6 | 37 |
Matched unrelated | 7 | 44 |
Mismatched related (haploidentical) | 3 | 19 |
Status at HCT | ||
CR1 | 7 | 44 |
CR2 | 2 | 12 |
Not in remission | 7 | 44 |
Cytogenetic risk | ||
Monosomal (+) | 9 | 56 |
Monosomal (−) | 7 | 44 |
Molecular | ||
TP53 (+) | 6 | 37 |
TP53 (−) | 7 | 44 |
TP53 (n/a) | 3 | 19 |
BM blast % at relapse (AML + MDS), median (range) | 21.5 (5-92) | - |
BM blast % at relapse (AML), median (range) | 26.5 (5-92) | - |
Prior GVHD before Pembrolizumab | ||
No | 10 | 63 |
Yes | 6 | 37 |
On immune suppression at pembrolizumab start | ||
No | 11 | 69 |
Yes | 5 | 31 |
Time of relapse post-HCT (range), d | 168.5 (66-1064) | - |
CR1, first complete remission; CR2, second complete remission; F, female; M, male.